Small renal masses (SRMs) are defi ned as lesions ≤4 cm in dimension, i.e. T1a . They are an increasingly common clinical scenario for practising urologists and physicians, and contemporary epidemiological studies indicate that SRMs account for nearly one half of all diagnosed renal masses diagnosed . SRMs are biologically heterogeneous with 20 % being benign lesions, while 20-30 % others are potentially aggressive at the time of diagnosis [ 1 ] ( Fig. 16.1 ).SRMs are slow growing, and the average growth rate of RCC is 0.28 cm/year . They seldom progress to metastasize, which was reported in only 1 % of patients [ 3 ]. However, the growth rate of a renal mass does not predict malignancy with certainty as even tumours with zero growth rate have a malignant potential [ 4 ]. Neither clinical nor radiographic features can reliably categorize SRMs as benign or malignant and differentiate between indolent and potentially aggressive tumours.So far, there is no established protocol for active surveillance of renal tumours. The tumour size may be an indicator of biological aggressiveness. In clinical T1b lesions (4-7 cm), the rate of tumour growth is 1.43 cm/year , and one out of nine patients develops metastasis. The risk of synchronous metastases increases to 22 % with each 1 cm rise in tumour size [ 5 ].Renal mass biopsy with molecular analysis can assess the aggressive potential and guide in decision-making between active surveillance and active treatment.